Dr. Jackson on Ongoing Challenges in Treating Patients With Multiple Myeloma

Graham Jackson, MD, PhD
Published: Friday, Mar 24, 2017



Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.

There are many challenges that oncologists are still facing in this field, including the fact that there is not a 100% cure rate, Jackson explains. There are a lot of patients with durable responses who have low-risk disease; however, for patients with high-risk disease who go through treatment lines very quickly, they are mostly transient responses, leading researchers to believe that this subpopulation is a higher unmet need.

Additionally, patients become refractory to several therapies. Results of the STORM study, which explored selinexor (KPT-330) in this population of patients, are intriguing, he adds. Novel agents moving through the pipeline are likely to lead excitement in the field.
 


Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses some of the ongoing challenges in the treatment of patients with multiple myeloma.

There are many challenges that oncologists are still facing in this field, including the fact that there is not a 100% cure rate, Jackson explains. There are a lot of patients with durable responses who have low-risk disease; however, for patients with high-risk disease who go through treatment lines very quickly, they are mostly transient responses, leading researchers to believe that this subpopulation is a higher unmet need.

Additionally, patients become refractory to several therapies. Results of the STORM study, which explored selinexor (KPT-330) in this population of patients, are intriguing, he adds. Novel agents moving through the pipeline are likely to lead excitement in the field.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Best Practice™: Choosing Therapies for Patients with EGFR-Mutant Lung Cancers: More Options... More Decisions... Better OutcomesFeb 28, 20182.0
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x